BioSpace News Archive

Genetown

SQZ Biotechnologies to Present at Jefferies Healthcare Conference - June 01, 2022

SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the Jefferies Healthcare Conference on June 8, in New York, NY.

June 1, 2022
·
2 min read
Genetown

Concert Pharmaceuticals Announces Pricing of Public Offering - June 02, 2022

Concert Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $4.75 per share.

June 1, 2022
·
4 min read
Drug Development

Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022

Transcenta Holding Limited announces that clinical data for the dose-escalation part of the Phase I study of TST001 in combination with CAPOX as the first line treatment of advanced and metastatic G/GEJ cancer has been published on the ASCO’s website: https://conferences.asco.org/am/attend.

June 1, 2022
·
6 min read
Policy

Press Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A

The United States Food and Drug Administration has granted Breakthrough Therapy designation to efanesoctocog alfa for the treatment of people with hemophilia A, a rare and life-threatening bleeding disorder, based on data from the pivotal XTEND-1 Phase 3 study.

June 1, 2022
·
8 min read
Business

SciNeuro Pharmaceuticals Announces a License and Option Agreement with GSK to Progress Development of Novel Therapies for CNS Diseases

SciNeuro Pharmaceuticals (SciNeuro), a leader in the discovery and development of innovative therapeutics for the treatment of CNS diseases, today announced the execution of an exclusive, worldwide license and option agreement with GlaxoSmithKline (GSK).

June 1, 2022
·
2 min read